Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?

BACKGROUND: Glioblastoma is an aggressive and almost universally fatal tumor. The prognosis at the time of recurrence has generally been poor, with overall survival typically in the range of 4–40 weeks. The merits of surgical resection (vs. open biopsy, to confirm recurrence via histology) in additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dardis, Christopher, Ashby, Lynn, Shapiro, William, Sanai, Nader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560929/
https://www.ncbi.nlm.nih.gov/pubmed/26341541
http://dx.doi.org/10.1186/s13104-015-1386-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560929/
https://www.ncbi.nlm.nih.gov/pubmed/26341541
http://dx.doi.org/10.1186/s13104-015-1386-3

Ejemplares similares